Precision-Guided (MALT-Targeting) Mucosal Vaccines
TOPIC 8. THE SCREENING TEST WE USED, TO IDENTIFY AND ISOLATE DENDRITIC CELLS WHICH HAD COMMITTED TO BECOMING ANTIGEN-PRESENTING CELLS (i.e., THEY HAD MOVED THEIR CCR7 RECEPTORS TO THEIR OUTER SURFACES), CHALLENGED MUCOSAL CELLS (FROM MALT PATCHES CONTACTED BY CANDIDATE PHAGES) TO SQUEEZE THROUGH 5-MICRON PORES IN A FILTER, TO GET TO HIGHER CONCENTRATIONS OF CCL19, THE CHEMO-ATTRACTANT WHICH, IN NATURE, LEADS ANTIGEN-PRESENTING CELLS TO GERMINAL CENTERS IN LYMPH NODES
As described on the first two pages of this website, the following factors shaped and guided the design of the screening test we created and used, to screen millions of “candidate/contestant” particles from a phage library, to identify those few particles which happened to be carrying randomly-generated peptide sequences which can be used to create better, more potent, faster-acting mucosal vaccines:
FACTOR 1: Our goal was to find a way to identify and isolate those few phages which were carrying (randomly-generated) foreign insert peptides, which could drive rapid uptake and processing by M cells and dendritic cells in the surface-mounted mucosal lymph nodes called MALT patches;
FACTOR 2: We learned/realized that a major cellular change occurs, when an “immature” (or pre-committed) dendritic cell transforms/activates/matures into a “mobile antigen-presenting cell”. That changes moves CCR7 proteins from inside the cell, to the outer surfaces of the cell, where they can be contacted by a chemo-attractant (CCL19) which will lead that cell to a “germinal center” inside a lymph node, where T and B cells will be waiting for an antigen delivery.
Therefore, we figured out how to create a physical obstacle, in the form of a filter with pores that were small enough to enable an activated dendritic cell to squeeze through, but only if it was “motivated” to do so.
Here is a condensed summary of how we performed the screening test:
STEP 1: Tiny droplets (containing 20 million phages from a phage library, for each mouse) were slowly “infused” (i.e., via a micro-pipette, rather than injected via a needle) into the nostrils of each mouse, in multiple different (sedated) mice;
STEP 2: We waited 90 minutes, to allow the droplets and phages to slowly travel through the nasal airways in the snout of the mouse, and to give the M cells and dendritic cells enough time to perform all five of the steps described HERE, but not enough time for the dendritic cells to digest and break apart the phages they had pulled in;
STEP 3: The mouse was anesthetized, then sacrificed. To slow down cellular activity and prevent activated dendritic cells from breaking apart the phages that had triggered their activation, ice-cold saline was forcibly injected into the aorta, and emerged from the vena cava. As an alternative faster approach, the head can be severed quickly, then placed in a refrigerator (or a freezer, for about 10-15 seconds, then moved to a refrigerator).
STEP 4: A “skull section” was created, which exposed the MALT patches in the nasal airways (which are in known locations, in mice and rats). Using a stereo-microscope, a very thin brush was used, with gentle pressure, to harvest surface and near-surface cells from the MALT patch locations.
STEP 5. The harvested phage-exposed mucosal cells were loaded into the top chamber of a dual-chamber vertical tube device, which had been custom-assembled from a sawed-off segment of a plastic pipette having a diameter that allowed the tube segment to be lowered, vertically, into a well on a 48-well ELISA plate. The bottom chamber (i.e., the bottom of the well on the plate) contained a supply of the CCL19 chemo-attractant, and enough liquid to rise above a horizontal filter disk, described below, to allow molecules of CCL19 to diffuse upward, through the filter, into the upper chamber containing the mucosal cells. The top and bottom chambers were separated from each other by a filter having pores with 5 micron diameters, which had been glued into place using a rubber ring as a gasket, to render the top chamber watertight (the bottom chamber did not need to be watertight).
Most animal cells have diameters of roughly 10 microns, and dendritic cells are even larger. However, they evolved with an ability to squeeze through the gaps between neighboring cells in soft tissues, in ways similar to the “pseudopod” travel of amoebas, or to how an octopus can squeeze through a small opening, to get to a crab or fish. Therefore, the only cells that were both ABLE . . . AND, MOTIVATED . . . to squeeze through the 5-micron pores in the filter, were dendritic cells which had already moved their CCR7 receptor proteins to their outer surfaces, by the time they were loaded into the separation tube.
STEP 6: The harvested phage-exposed cells were given two hours (at body temperature), to give any activated/transformed dendritic cells time to squeeze through the filter. The separation tube was then lifted out and discarded, and any cells that had reached the bottom chamber were broken apart, by a detergent that breaks apart cell membranes, but not phages enclosed within proteins. When the cells were broken open, whatever they released was plated onto a “lawn” of fresh host bacteria cells, on an agar plate.
STEP 7: Within two days, a few phage colonies began to appear, and “clonal isolates” from each colony was transferred into a fresh batch of host cells, in broth. When enough new “clonal” phages (i.e., all descended from a single ancestor, and having the same genetic content) had reproduced, the phages were purified, and a DNA preparation was made from each clonal isolate. The “foreign insert” sequences were “amplified”, by polymerase chain reaction (PCR), and those DNA preparations were shipped to a DNA sequencing lab.
The resulting DNA sequences revealed what the amino acid sequences were, in the phages that had “won” the competition created by the screening test. Those were the phages which were carrying randomly-generated “foreign insert peptides” which had functioned – successfully and effectively – as “MALT-targeting HYPER-pathogen peptides”, which had been able to initiate, and then drive all the way to completion, not just one or two cellular responses, but an entire series of five different and distinct cellular responses, by two different types of immune cells, leading to an irrevocable commitment, by a previously immature dendritic cell, to become an antigen-presenting cell.
Additional comments:
1. The amino acid sequences of the CCL19 chemo-attractant protein vary, between different species, but those sequences, for all animal types that are likely to be useful in research (including mice, rats, ferrets, dogs, cats, pigs, monkeys, chimps, ducks, and humans) are known, and can be readily located via Medline searches and gene databases. In addition, various versions (including from mice, rats, and humans) are readily available for purchase.
2. Anyone who looks into the CCL19 chemo-attractant cytokine will be likely to also see references to CCL21, which can perform in similar ways. We’re not experts on the distinctions between those two molecules, but it appears (and we assume and believe) that: (i) CCL21 has other, additional effects (such as on T cells) which would not be helpful in the screening test we used; and, (ii) it does not appear that both CCL19 >> AND << CCL21 need to be present (as co-factors or similar agents), to get CCL19 to work. Therefore, we ignored CCL21, and only used CCL19. If any experts believe that assumption and decision was incorrect or incomplete, they are requested to contact us.
3. As described on the “Plans & Goals” page of this website (see the button in the footer), we do NOT hope, want, or intend to ever become a manufacturing company, or to assemble the types of safety facilities and super-high expertise that would allow us to perform things like “pathogen challenge tests”. Instead, our goal is to become a licensing company, and to work and cooperate with dozens of animal vaccine companies, to help them create and sell hundreds of different vaccines, for dozens of different animal types. Accordingly, we hereby offer to provide detailed step-by-step instructions (with reagent names and concentrations, incubation times and temperatures, and all other details) for how to perform these types of screening tests, to any vaccine company or research group that has the facilities needed to perform these types of tests. So, any company or research group that qualifies is invited to contact us, via the last page in this website.